RxDoctor Payments Data

Rose Shorter, MD

Internal Medicine · Wareham, MANPI 1861430852

Payments from drug & device makers

$502in general payments, 2019–2025

Across 19 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$239
  • Abbott$87
  • Novo Nordisk$76
  • Dexcom, Inc.$25
  • Nestle Healthcare Nutrition Inc.$22
  • Astellas Pharma US Inc$20
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$502 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$181,763
Medicare patients
340
Services billed
2,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$67,405
JardianceEmpagliflozin56$50,109
EliquisApixaban22$30,461
WegovySemaglutide11$14,675
RybelsusSemaglutide12$14,275
Breo ElliptaFluticasone/Vilanterol31$12,475
JanuviaSitagliptin Phosphate14$12,008
MyrbetriqMirabegron16$10,572
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,756
RestasisCyclosporine11$6,981
Combivent RespimatIpratropium/Albuterol Sulfate13$6,773
Rosuvastatin Calcium148$4,196
Lidocaine22$3,780
Aripiprazole39$3,730
Atorvastatin Calcium270$3,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$76$96,35464 claims
PfizerEliquis$17$30,46122 claims
MerckJanuvia$17$12,00814 claims
Astellas Pharma US IncMyrbetriq$20$10,57216 claims
AbbVieRestasis, Synthroid$239$8,29941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Wareham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →